The Novel Use of GLP-1 Analogue and Insulin Combination in Type 2 Diabetes Mellitus

E-ISSN： 2212-3334|6|2|129-135

ISSN： 1872-2148

Source： Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol.6, Iss.2, 2012-05, pp. : 129-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 3, 2007-11 ,pp. : 193-201

Bentham Science Publishers

Access to resources Recommend Favorite

Liraglutide-A Novel GLP-1 Analogue

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 3, Iss. 3, 2009-11 ,pp. : 200-204

Bentham Science Publishers

Access to resources Recommend Favorite

Biphasic (Premix) Insulin Analogs in Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 2, Iss. 2, 2008-06 ,pp. : 129-134

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Approaches to the Treatment of Obesity and Type 2 Diabetes Mellitus: Bioactive Leptin-Related Synthetic Peptide Analogs

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 5, Iss. 3, 2011-09 ,pp. : 163-175

Bentham Science Publishers

Access to resources Recommend Favorite

Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 5, Iss. 1, 2011-01 ,pp. : 66-73

Bentham Science Publishers

Access to resources Recommend Favorite